Evaluation of the association between HIF-1α and HER-2 expression, hormone receptor status, Ki-67 expression, histology and tumor FDG uptake in breast cancer

Cerci,Sevi̇m  Sureyya; Bozkurt,Kemal  Kursat; Eroglu,Hasan  Erol; Cerci,Celal; Erdemoglu,Evri̇m; Bulbul,Pinar  Talip; Cetin,Meltem; Cetin,Recep; Ciris,Ibrahim  Metin; Bulbul,Mahmut

doi:10.3892/ol.2016.5199

Evaluation of the association between HIF-1α and HER-2 expression, hormone receptor status, Ki-67 expression, histology and tumor FDG uptake in breast cancer

Authors:
- Sevi̇m Sureyya Cerci
- Kemal Kursat Bozkurt
- Hasan Erol Eroglu
- Celal Cerci
- Evri̇m Erdemoglu
- Pinar Talip Bulbul
- Meltem Cetin
- Recep Cetin
- Ibrahim Metin Ciris
- Mahmut Bulbul
View Affiliations

Affiliations: Department of Nuclear Medicine, Süleyman Demirel University Hospital, Isparta 32260, Turkey, Department of Pathology, Süleyman Demirel University Hospital, Isparta 32260, Turkey, Department of Oncologic Surgery, Süleyman Demirel University Hospital, Isparta 32260, Turkey, Department of General Surgery, Sifa Hospital, Isparta 32200, Turkey, Department of Gynecologic Oncology, Süleyman Demirel University Hospital, Isparta 32260, Turkey, Department of Radiology, Atatürk Teaching and Research Hospital, University of Kâtip Celebi, Izmir 35360, Turkey, Department of General Surgery, Süleyman Demirel University Hospital, Isparta 32260, Turkey
Published online on: September 28, 2016 https://doi.org/10.3892/ol.2016.5199
Pages: 3889-3895
Copyright: © Cerci et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to examine hypoxia-inducible factor (HIF)-1α expression and its association with glucose uptake in invasive breast cancer. In addition, connections between glucose uptake and several other prognostic parameters of breast cancer were studied. Between August 2013 and April 2015, 92 patients with biopsy-diagnosed breast cancer were subjected to 18F-fluorodeoxyglucose positron emission tomography/computed tomography. The primary tumor and nodal maximum standardized uptake values (SUVmax) were recorded, and HIF-1α expression and clinical parameters, including tumor mass, estrogen receptor (ER) and progesterone receptor (PgR) levels, human epidermal growth factor receptor-2 (HER-2), Ki-67 index, grade and histology, were analyzed. SUVmax was compared with clinicopathological parameters and HIF-1α expression. The median SUVmax values of the ER-negative and PgR-negative tumors were significantly increased compared with ER and PgR-positive tumors, respectively (P=0.004 and P=0.008). SUVmax differed significantly between the T2 and T3 tumors and the T1 tumors. The median SUVmax levels were higher in the Ki-67 expression >10% group than the Ki-67 index <10% group (P=0.001). Although the median SUVmax values in HER-2-positive and -negative tumors were similar, triple-negative tumors demonstrated significantly higher values (P=0.04). With regard to tumor grade, the median SUVmax was greater in the high-grade tumors compared with the low-grade tumors. SUVmax did not exhibit a significant correlation with HIF-1α expression; however, HIF-1α expression was associated with tumor size and PgR expression. HIF-1α expression increased with a larger tumor size (r=0.27; P=0.008) and decreased PgR expression (r=-0.26; P=0.0002). The axillary nodal SUVmax of the N1 tumors was significantly lower than the N2 and N3 tumors (P<0.0001). In the multivariate analysis, tumor size, Ki-67 expression and ER Allred score were independent factors that impacted SUVmax. The results of the present study indicated strong associations between tumor size, tumor grade, Ki-67 expression, triple-negativity, downregulated hormone receptor expression and SUVmax values. Conversely, there was no association observed between glucose uptake and levels of HIF-1α. Based on these results, it is suggested that the lack of assiocation between hypoxia and glucose uptake indicates phenotypic independence.

View Figures

View References

1	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI
2	Knowles HJ and Harris AL: Hypoxia and oxidative stress in breast cancer. Hypoxia and tumourigenesis. Breast Cancer Res. 3:318–322. 2001. View Article : Google Scholar : PubMed/NCBI
3	Serganova I, Humm J, Ling C and Blasberg R: Tumor hypoxia imaging. Clin Cancer Res. 12:5260–5264. 2006. View Article : Google Scholar : PubMed/NCBI
4	Bos R, van der Groep P, Greijer AE, Shvarts A, Meijer S, Pinedo HM, Semenza GL, van Diest PJ and van der Wall E: Levels of hypoxia-inducible Factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma. Cancer. 97:1573–1581. 2003. View Article : Google Scholar : PubMed/NCBI
5	Wang GL, Jiang BH, Rue EA and Semenza GL: Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA. 92:5510–5514. 1995. View Article : Google Scholar : PubMed/NCBI
6	Yu AY, Frid MG, Shimoda LA, Wiener CM, Stenmark K and Semenza GL: Temporal, spatial, and oxygen-regulated expression of hypoxia-inducible factor-1 in the lung. Am J Physiol. 275:L818–L826. 1998.PubMed/NCBI
7	Huang LE, Arany Z, Livingston DM and Bunn HF: Activation of hypoxia-inducible transcription factor depends primarily upon redox-sensitive stabilization of its apha subunit. J Biol Chem. 271:32253–32259. 1996. View Article : Google Scholar : PubMed/NCBI
8	Bos R, Zhong H, Hanrahan CF, Mommers EC, Semenza GL, Pinedo HM, Abeloff MD, Simons JW, van Diest PJ and van der Wall E: Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis. J Natl Cancer Inst. 93:309–314. 2001. View Article : Google Scholar : PubMed/NCBI
9	Rajendran JG, Mankoff DA, O'Sullivan F, Peterson LM, Schwartz DL, Conrad EU, Spence AM, Muzi M, Farwell DG and Krohn KA: Hypoxia and glucose metabolism in malignant tumors: Evaluation by [18F]fluoromisonidazole and [18F]fluorodeoxyglucose positron emission tomography imaging. Clin Cancer Res. 10:2245–2252. 2004. View Article : Google Scholar : PubMed/NCBI
10	Burgman P, Odonoghue JA, Humm JL and Ling CC: Hypoxia-induced increase in FDG uptake in MCF7 cells. J Nucl Med. 42:170–175. 2001.PubMed/NCBI
11	Warburg O: The Metabolism of Tumors. Richard R., Inc.; New York, NY: pp. 129–169. 1931
12	Song BI, Lee SW, Jeong SY, Chae YS, Lee WK, Ahn BC and Lee J: 18F-FDG uptake by metastatic axillary lymph nodes on pretreatment PET/CT as a prognostic factor for recurrence in patients with invasive ductal breast cancer. J Nucl Med. 53:1337–1344. 2012. View Article : Google Scholar : PubMed/NCBI
13	Czernin J and Phelps ME: Positron emission tomography scanning: Current and future applications. Annu Rev Med. 53:89–112. 2002. View Article : Google Scholar : PubMed/NCBI
14	Avril N, Rosé CA, Schelling M, Dose J, Kuhn W, Bense S, Weber W, Ziegler S, Graeff H and Schwaiger M: Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: Use and limitations. J Clin Oncol. 18:3495–3502. 2000.PubMed/NCBI
15	Buck A, Schirrmeister H, Kühn T, Shen C, Kalker T, Kotzerke J, Dankerl A, Glatting G, Reske S and Mattfeldt T: FDG uptake in breast cancer: Correlation with biological and clinical prognostic parameters. Eur J Nucl Med Mol Imaging. 29:1317–1323. 2002. View Article : Google Scholar : PubMed/NCBI
16	Ueda S, Tsuda H, Asakawa H, Shigekawa T, Fukatsu K, Kondo N, Yamamoto M, Hama Y, Tamura K, Ishida J, et al: Clinicopathological and prognosti relevance of uptake level using 18F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in primary breast cancer. Jpn J Clin Oncol. 38:250–258. 2008. View Article : Google Scholar : PubMed/NCBI
17	Sanli Y, Kuyumcu S, Ozkan ZG, Işİk G, Karanlik H, Guzelbey B, Turkmen C, Ozel S, Yavuz E and Mudun A: Increased FDG uptake in breast cancer is associated with prognostic factors. Ann Nucl Med. 26:345–350. 2012. View Article : Google Scholar : PubMed/NCBI
18	Fitzgibbons PL, Page DL, Weaver D, Thor AD, Allred DC, Clark GM, Ruby SG, O'Malley F, Simpson JF, Connolly JL, et al: Prognostic factors in breast cancer. Collage of american pathologists consensus statement 1999. Arch Pathol Lab Med. 124:966–978. 2000.PubMed/NCBI
19	Lakhani SR, Ellis IO, Schnitt SJ, Tan PH and van de Vijver MJ: WHO Classification of tumours of the breast. 4th. IARC; Lyon, France: 2012
20	Dales JP, Garcia S, Meunier-Carpentier S, Andrac-Meyer L, Haddad O, Lavaut MN, Allasia C, Bonnier P and Charpin C: Overexpression of hypoxia-inducible factor HIF-1 alpha predicts early relapse in breast cancer: Retrospective study in a series of 745 patients. Int J Cancer. 116:734–739. 2005. View Article : Google Scholar : PubMed/NCBI
21	Cohen DA, Dabbs DJ, Cooper KL, Amin M, Jones TE, Jones MW, Chivukula M, Trucco GA and Bhargava R: Interobserver agreement among pathologists for semiquantitative hormone receptorscoring in breast carcinoma. Am J Clin Pathol. 138:796–802. 2012. View Article : Google Scholar : PubMed/NCBI
22	Koolen BB, Peeters MJ Vrancken, Wesseling J, Lips EH, Vogel WV, Aukema TS, van Werkhoven E, Gilhuijs KG, Rodenhuis S, Rutgers EJ and Valdés Olmora RA: Association of primary tumour FDG uptake with clinical, histopathological and molecular characteristics in breast cancer patients scheduled for neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging. 39:1830–1838. 2012. View Article : Google Scholar : PubMed/NCBI
23	Groheux D, Giacchetti S, Moretti JL, Porcher R, Espié M, Lehmann-Che J, de Roquancourt A, Hamy AS, Cuvier C, Vercellino L and Hindié E: Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer. Eur J Nucl Med Mol Imaging. 38:426–435. 2011. View Article : Google Scholar : PubMed/NCBI
24	Heudel P, Cimarelli S, Montella A, Bouteille C and Mognetti T: Value of PET-FDG in primary breast cancer based on histopathological and immunohistochemical prognostic factors. Int J Clin Oncol. 15:588–593. 2010. View Article : Google Scholar : PubMed/NCBI
25	Bos R, van Der Hoeven JJ, van Der Wall E, van Der Groep P, van Diest PJ, Comans EF, Joshi U, Semenza GL, Hoekstra OS, Lammertsma AA and Molthoff CF: Bioglogic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol. 20:379–387. 2002. View Article : Google Scholar : PubMed/NCBI
26	Oshida M, Uno K, Suzuki M, Nagashima T, Hashimoto H, Yagata H, Shishikura T, Imazeki K and Nakajima N: Predicting the prognoses of breast carcinoma patients with positron emission tomography using 2-deoxy-2-fluoro[18F]-D-glucose. Cancer. 82:2227–2234. 1998. View Article : Google Scholar : PubMed/NCBI
27	Buck AC, Schirrmeister HH, Guhlmann CA, Diederichs CG, Shen C, Buchmann I, Kotzerke J, Birk D, Mattfeldt T and Reske SN: Ki-67 immunostaining in pancreatic cancer and chronic active pancreatitis: Does in vivo FDG uptake correlate with proliferative activity? J Nucl Med. 42:721–725. 2001.PubMed/NCBI
28	Higashi K, Clavo AC and Wahl RL: Does FDG uptake measure proliferative activity of human cancer cells? In vitro comparison with DNA flow cytometry and tritiated thymidine uptake. J Nucl Med. 34:414–419. 1993.PubMed/NCBI
29	Simpson JF, Gray R, Dressler LG, Cobau CD, Falkson CI, Gilchrist KW, Pandya KJ, Page DL and Robert NJ: Prognostic value of histologic grade and proliferative activity in axillary node-positive breast cancer: Results from the Eastern Cooperative Oncology Group Companion Study, EST 4189. J Clin Oncol. 18:2059–2069. 2000.PubMed/NCBI
30	Gil-Rendo A, Martínez-Regueira F, Zornoza G, Garcia-Velloso MJ, Beorlegui C and Rodriguez-Spiteri N: Association between [18F]fluorodeoxyglucose uptake and prognostic parameters in breast cancer. Br J Surg. 96:166–170. 2009. View Article : Google Scholar : PubMed/NCBI
31	Nakajo M, Kajiya Y, Kaneko T, Kaneko Y, Takasaki T, Tani A, Ueno M, Koriyama C and Nakajo M: FDG PET/CT and diffusion-weighted imaging for breast cancer: Prognostic value of maximum standardized uptake values and apparent diffusion coefficient values of the primary lesion. Eur J Nucl Med Mol Imaging. 37:2011–2020. 2010. View Article : Google Scholar : PubMed/NCBI
32	Osborne JR, Port E, Gonen M, Doane A, Yeung H, Gerald W, Cook JB and Larson S: 18F-FDG PET of locally invasive breast cancer and association of estrogen receptor status with standardized uptake value: Microarray and immunohistochemical analysis. J Nucl Med. 51:543–550. 2010. View Article : Google Scholar : PubMed/NCBI
33	Berriolo-Riedinger A, Touzery C, Riedinger JM, Toubeau M, Coudert B, Arnould L, Boichot C, Cochet A, Fumoleau P and Brunotte F: [18F]FDG-PET predicts complete pathological response of breast cancer to neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging. 34:1915–1924. 2007. View Article : Google Scholar : PubMed/NCBI
34	Kumar R, Chauhan A, Zhuang H, Chandra P, Schnall M and Alavi A: Clinicopathologic factors associated with false negative FDG-PET in primary breast cancer. Breast Cancer Res Treat. 98:267–274. 2006. View Article : Google Scholar : PubMed/NCBI
35	Crippa F, Seregni E, Agresti R, Chiesa C, Pascali C, Bogni A, Decise D, De Sanctis V, Greco M, Daidone MG and Bombardieri E: Association between [18F]fluorodeoxyglucose uptake and postoperative histopathology, hormone receptor status, thymidine labelling index and p53 in primary breast cancer: A preliminary observation. Eur J Nucl Med. 25:1429–1434. 1998. View Article : Google Scholar : PubMed/NCBI
36	Avril N, Rosé CA, Schelling M, Dose J, Kuhn W, Bense S, Weber W, Ziegler S, Graeff H and Schwaiger M: Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: Use and limitations. J Clin Oncol. 18:3495–3502. 2000.PubMed/NCBI
37	Kim BS and Sung SH: Usefulness of 18F-FDG uptake with clinicopathologic and immunohistochemical prognostic factors in breast cancer. Ann Nucl Med. 26:175–183. 2012. View Article : Google Scholar : PubMed/NCBI
38	Mavi A, Cermik TF, Urhan M, Puskulcu H, Basu S, Yu JQ, Zhuang H, Czerniecki B and Alavi A: The effects of estrogen, progesterone, and C-erbB-2 receptor states on 18F-FDG uptake of primary breast cancer lesions. J Nucl Med. 48:1266–1272. 2007. View Article : Google Scholar : PubMed/NCBI
39	Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, et al: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 353:1673–1684. 2005. View Article : Google Scholar : PubMed/NCBI
40	Piccart M, Lohrish C, Di Leo A and Larsimont D: The predictive value of HER2 in breast cancer. Oncology. 61(Suppl 2): 73–82. 2001. View Article : Google Scholar : PubMed/NCBI
41	Gonzalez-Angulo AM, Hortobagyi GN and Esteva FJ: Adjuvant therapy with trastuzumab for HER-2/neu-positive breast cancer. Oncologist. 11:857–867. 2006. View Article : Google Scholar : PubMed/NCBI
42	Ikenaga N, Otomo N, Toyofuku A, Ueda Y, Toyoda K, Hayashi T, Nishikawa K and Tanaka M: Standardized uptake values for breast carcinomas assessed by fluorodeoxyglucose-positron emission tomography correlate with prognostic factors. Am Surg. 73:1151–1157. 2007.PubMed/NCBI
43	Spence AM, Muzi M, Graham MM, O'Sullivan F, Krohn KA, Link JM, Lewellen TK, Lewellen B, Freeman SD, Berger MS and Ojemann GA: Glucose metebolism in human malignant gliomas measured quantitatively with PET, 1-[C-11]glucose and FDG: Analysis of the FDG lumped constant. J Nucl Med. 39:440–448. 1998.PubMed/NCBI
44	Kallinowski F, Schlenger KH, Kloes M, Stohrer M and Vaupel P: Tumor blood flow: The principal modulator of oxidative and glycolytic metablism and of the metabolic micromilieu of human tumor xenografts in vivo. Int J Cancer. 44:266–272. 1989. View Article : Google Scholar : PubMed/NCBI
45	Fleming IN, Manavaki R, Blower PJ, West C, William KJ, Harris AL, Domarkas J, Lord S, Baldry C and Gilbert FJ: Imaging tumour hypoxia with positron emission tomography. Br J Cancer. 112:238–250. 2015. View Article : Google Scholar : PubMed/NCBI
46	Evans SM, Hahn SM, Magarelli DP and Koch CJ: Hypoxic heterogeneity in human tumors: EF5 binding, vasculature, necrosis and proliferation. Am J Clin Oncol. 24:467–472. 2001. View Article : Google Scholar : PubMed/NCBI
47	Clavo AC, Brown RS and Wahl RL: Fluorodeoxyglucose uptake in human cancer cell lines is increased by hypoxia. J Nucl Med. 36:1625–1632. 1995.PubMed/NCBI
48	Toba H, Kondo K, Sadohara Y, Otsuka H, Morimoto M, Kajiura K, Nakagawa Y, Yoshida M, Kawakami Y, Takizawa H, et al: 18F-fluorodeoxyglucose positron emission tomography/computed tomography and the relationship between fluorodeoxyglucose uptake and the expression of hypoxia-inducible factor-1α, glucose transporter-1 and vascular endothelial growth factor in thymic epithelial tumours. Eur J Cardiothorac Surg. 44:105–112. 2013. View Article : Google Scholar